Sugi Predict

Sugi Predict / Targets / DMPK

DMPK

Myotonin-protein kinase · Q09013 · DMPK on Sugi Atlas →

5,214 patent compounds predicted against DMPK, 3,968 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Tofacitinib Tofacitinib (SCHEMBL322753) 1.00 2/20
Tofacitinib Tofacitinib (SCHEMBL1120705) 1.00 2/20
Tofacitinib Tofacitinib (SCHEMBL1374185) 1.00 2/20
SCHEMBL2323500 SCHEMBL2323500 0.85 2/20
SCHEMBL3065509 SCHEMBL3065509 0.85 2/20
SCHEMBL2963866 SCHEMBL2963866 0.80 2/20
SCHEMBL1446583 SCHEMBL1446583 0.80 2/20
SCHEMBL2320931 SCHEMBL2320931 0.80 2/20
SCHEMBL3683647 SCHEMBL3683647 0.80 2/20
SCHEMBL4061567 SCHEMBL4061567 0.78 2/20
SCHEMBL1846276 SCHEMBL1846276 0.78 2/20
SCHEMBL2319641 SCHEMBL2319641 0.77 2/20
SCHEMBL3678056 SCHEMBL3678056 0.77 2/20
SCHEMBL4062773 SCHEMBL4062773 0.77 2/20
SCHEMBL1446406 SCHEMBL1446406 0.76 2/20
SCHEMBL1446409 SCHEMBL1446409 0.76 2/20
SCHEMBL1446147 SCHEMBL1446147 0.76 2/20
SCHEMBL2148397 SCHEMBL2148397 0.75 2/20
SCHEMBL353500 SCHEMBL353500 0.75 2/20
SCHEMBL2319231 SCHEMBL2319231 0.75 2/20

Clinical trials — most relevant to DMPK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway PHASE4COMPLETED
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate PHASE2/PHASE3WITHDRAWN
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy PHASE2RECRUITING
A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 PHASE1/PHASE2COMPLETED
Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women? PHASE2COMPLETED
Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy PHASE1/PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction PHASE2UNKNOWN
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype PHASE2RECRUITING
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
Therapeutic RSK1 Targeting in Myelofibrosis PHASE1RECRUITING
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Tumor Kinase Inhibitor Concentrations Measured by PET nanCOMPLETED
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States nanCOMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED
The Effect of White Tea Consumption on Obesity nanCOMPLETED
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation nanCOMPLETED
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a DMPK binder may also engage these)

ProteinNameSimilarity
P54265 — 1.000 P54265 →
CDC42BPG Serine/threonine-protein kinase MRCK gamma 0.987 landscape →
Q8K330 — 0.986 Q8K330 →
STK32C Serine/threonine-protein kinase 32C 0.985 landscape →
Q80XI6 — 0.984 Q80XI6 →
Q9Y6S9 — 0.984 Q9Y6S9 →
Q80UW5 — 0.983 Q80UW5 →
Q66HA1 — 0.982 Q66HA1 →
Q5RA67 — 0.982 Q5RA67 →
Q9Z2A6 — 0.982 Q9Z2A6 →
Q96LW2 — 0.982 Q96LW2 →
Q8R2S1 — 0.982 Q8R2S1 →
RAPGEF3 Rap guanine nucleotide exchange factor 3 0.982 landscape →
Q5RJI5 — 0.981 Q5RJI5 →
Q99ML2 — 0.981 Q99ML2 →
O54967 — 0.981 O54967 →
TNK1 Non-receptor tyrosine-protein kinase TNK1 0.981 landscape →
Q9R117 — 0.981 Q9R117 →
B2DD29 — 0.981 B2DD29 →
O75064 — 0.981 O75064 →
Q8VCC8 — 0.980 Q8VCC8 →
KCNH3 Voltage-gated inwardly rectifying potassium channel KCNH3 0.980 landscape →
A5PKJ4 — 0.980 A5PKJ4 →
Q562E7 — 0.980 Q562E7 →
MAP3K6 Mitogen-activated protein kinase kinase kinase 6 0.980 landscape →
Q9R011 — 0.980 Q9R011 →
Q96P48 — 0.980 Q96P48 →
Q8CIE4 — 0.980 Q8CIE4 →
Q8WWN8 — 0.979 Q8WWN8 →
Q80Y86 — 0.979 Q80Y86 →